Shares of Ingevity Corporation (NYSE:NGVT – Get Free Report) have received a consensus rating of “Hold” from the five brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $80.00.
Several brokerages have recently issued reports on NGVT. Zacks Research upgraded shares of Ingevity to a “hold” rating in a report on Tuesday, December 16th. Wall Street Zen downgraded Ingevity from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 9th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $83.00 price objective on shares of Ingevity in a research note on Monday, March 2nd. Jefferies Financial Group reissued a “buy” rating and set a $82.00 target price on shares of Ingevity in a research report on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Ingevity in a report on Thursday, January 22nd.
Get Our Latest Report on Ingevity
Institutional Trading of Ingevity
Ingevity Stock Up 3.3%
Ingevity stock opened at $71.80 on Monday. Ingevity has a one year low of $28.49 and a one year high of $77.46. The stock has a market cap of $2.53 billion, a PE ratio of -15.44 and a beta of 1.31. The company has a debt-to-equity ratio of 39.10, a quick ratio of 0.79 and a current ratio of 1.33. The stock has a fifty day moving average of $69.17 and a 200 day moving average of $60.43.
Ingevity (NYSE:NGVT – Get Free Report) last released its earnings results on Wednesday, February 25th. The company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.16). The company had revenue of $255.10 million for the quarter, compared to analysts’ expectations of $257.27 million. Ingevity had a negative net margin of 13.51% and a positive return on equity of 126.25%. Ingevity’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.95 earnings per share. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. As a group, sell-side analysts predict that Ingevity will post 4.45 EPS for the current year.
Ingevity Company Profile
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Featured Stories
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
